{"id":1001031,"date":"2026-09-08T07:09:47","date_gmt":"2026-09-08T11:09:47","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/"},"modified":"2026-09-08T07:09:47","modified_gmt":"2026-09-08T11:09:47","slug":"calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/","title":{"rendered":"CalciMedica to Participate in the H.C. Wainwright 28th\u00a0Annual Global Investment Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">LA JOLLA, Calif., Sept.  08, 2026  (GLOBE NEWSWIRE) &#8212; CalciMedica, Inc. (\u201cCalciMedica\u201d or the \u201cCompany\u201d) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that Management will present and participate in 1&#215;1 investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026.<\/p>\n<p align=\"left\">\n        <strong>About CalciMedica<\/strong><br \/>\n        <br \/>CalciMedica is a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases. The Company&#8217;s pipeline includes two distinct CRAC channel inhibitor compounds: zegocractin, which is formulated for intravenous administration as Auxora<sup>\u2122<\/sup>, and CM5480, which is designed for chronic oral dosing. Auxora has been evaluated in more than 350 patients and is being developed for pulmonary arterial hypertension and acute pancreatitis, including a planned Phase 1b proof-of-concept trial in PAH and a planned Phase 2b trial in acute pancreatitis. CM5480 is being developed for pulmonary hypertension, with an IND submission anticipated in mid-2027. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LA4r0VqiLiZdngexrQVX-h-sEmGeWvZD4POEj-1TGUgKE96j9bUvhvbK6KhkuXpE76JOma4V4cuHaAbb9NY73276S2feVihJYWLPdkOHOKY=\" rel=\"nofollow\" target=\"_blank\">www.calcimedica.com<\/a>.<\/p>\n<p align=\"left\">\n        <strong>Investor Relations Contact<\/strong><br \/>\n        <br \/>Joyce Allaire<br \/>LifeSci Advisors, LLC<br \/>jallaire@lifesciadvisors.com<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTI2NCM3ODE3NjU3IzUwMDE2NTk1Ng==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NmExYzhiYWEtMTFiMi00Yzk5LTgxYjgtZDY1ODU1NWI0ZGNlLTUwMDE2NTk1Ni0yMDI2LTA5LTA4LWVu\/tiny\/CalciMedica-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) &#8212; CalciMedica, Inc. (\u201cCalciMedica\u201d or the \u201cCompany\u201d) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that Management will present and participate in 1&#215;1 investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026. About CalciMedica CalciMedica is a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases. The Company&#8217;s pipeline includes two distinct CRAC channel inhibitor compounds: zegocractin, which is formulated for intravenous administration as Auxora\u2122, and CM5480, which is designed for chronic oral dosing. Auxora has been evaluated in &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;CalciMedica to Participate in the H.C. Wainwright 28th\u00a0Annual Global Investment Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1001031","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CalciMedica to Participate in the H.C. Wainwright 28th\u00a0Annual Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CalciMedica to Participate in the H.C. Wainwright 28th\u00a0Annual Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) &#8212; CalciMedica, Inc. (\u201cCalciMedica\u201d or the \u201cCompany\u201d) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that Management will present and participate in 1&#215;1 investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026. About CalciMedica CalciMedica is a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases. The Company&#8217;s pipeline includes two distinct CRAC channel inhibitor compounds: zegocractin, which is formulated for intravenous administration as Auxora\u2122, and CM5480, which is designed for chronic oral dosing. Auxora has been evaluated in &hellip; Continue reading &quot;CalciMedica to Participate in the H.C. Wainwright 28th\u00a0Annual Global Investment Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-08T11:09:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTI2NCM3ODE3NjU3IzUwMDE2NTk1Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"CalciMedica to Participate in the H.C. Wainwright 28th\u00a0Annual Global Investment Conference\",\"datePublished\":\"2026-09-08T11:09:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/\"},\"wordCount\":194,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMTI2NCM3ODE3NjU3IzUwMDE2NTk1Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/\",\"name\":\"CalciMedica to Participate in the H.C. Wainwright 28th\u00a0Annual Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMTI2NCM3ODE3NjU3IzUwMDE2NTk1Ng==\",\"datePublished\":\"2026-09-08T11:09:47+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMTI2NCM3ODE3NjU3IzUwMDE2NTk1Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMTI2NCM3ODE3NjU3IzUwMDE2NTk1Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CalciMedica to Participate in the H.C. Wainwright 28th\u00a0Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CalciMedica to Participate in the H.C. Wainwright 28th\u00a0Annual Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"CalciMedica to Participate in the H.C. Wainwright 28th\u00a0Annual Global Investment Conference - Market Newsdesk","og_description":"LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) &#8212; CalciMedica, Inc. (\u201cCalciMedica\u201d or the \u201cCompany\u201d) (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that Management will present and participate in 1&#215;1 investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026. About CalciMedica CalciMedica is a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases. The Company&#8217;s pipeline includes two distinct CRAC channel inhibitor compounds: zegocractin, which is formulated for intravenous administration as Auxora\u2122, and CM5480, which is designed for chronic oral dosing. Auxora has been evaluated in &hellip; Continue reading \"CalciMedica to Participate in the H.C. Wainwright 28th\u00a0Annual Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-08T11:09:47+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTI2NCM3ODE3NjU3IzUwMDE2NTk1Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"CalciMedica to Participate in the H.C. Wainwright 28th\u00a0Annual Global Investment Conference","datePublished":"2026-09-08T11:09:47+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/"},"wordCount":194,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTI2NCM3ODE3NjU3IzUwMDE2NTk1Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/","name":"CalciMedica to Participate in the H.C. Wainwright 28th\u00a0Annual Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTI2NCM3ODE3NjU3IzUwMDE2NTk1Ng==","datePublished":"2026-09-08T11:09:47+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTI2NCM3ODE3NjU3IzUwMDE2NTk1Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMTI2NCM3ODE3NjU3IzUwMDE2NTk1Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/calcimedica-to-participate-in-the-h-c-wainwright-28th-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"CalciMedica to Participate in the H.C. Wainwright 28th\u00a0Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1001031","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1001031"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1001031\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1001031"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1001031"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1001031"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}